ONCAlert | Upfront Therapy for mRCC
Videos  >  

Telemedicine Improves Accessibility of CAR T-Cell Therapy

Sarah Murawski, MPAS
Published Online:8:41 PM, Tue November 26, 2019


Sarah Murawski, MPAS, physician assistant in Medicine at the Vanderbilt University Medical Center, discusses how telemedicine can impact the use of chimeric antigen receptor (CAR) T-cell therapy in patients with cancer at the Association of Community Cancer Centers (ACCC) National Oncology Conference.

CAR T-cell therapy is still new. Murawski says we don’t know a lot about these agents, but telemedicine will be essential and provide more patients with access to this treatment. Currently, CAR T-cell therapy is not offered at every institution.

Hospitals must be specifically certified to provide patients with CAR T-cell therapy, says Murawski. With telemedicine, more patients with cancer can gain access to this treatment. The level of safety in administering this therapy will increase. Additionally, patients do not have to spend as much time in the hospital, which addresses issues with financial toxicities, Murawski concludes. Patients aren’t taking on the high costs that are associated with CAR T-cell therapy.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.